Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

CytoDyn Inc_INT sell geldnutzer

Start price
€1.28
10.07.21 / 50%
Target price
€0.80
10.07.22
Performance (%)
-30.80%
End price
€0.88
20.12.21
Summary
This prediction ended on 20.12.21 with a price of €0.88. The SELL prediction by geldnutzer for CytoDyn Inc_INT performed very well with a performance of -30.80%. geldnutzer has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
CytoDyn Inc_INT - - -
iShares Core DAX® 0.000% -2.064% 13.111%
iShares Nasdaq 100 0.626% -2.884% 37.744%
iShares Nikkei 225® 1.568% -5.892% 19.592%
iShares S&P 500 0.334% -2.281% 27.745%

According to geldnutzer what are the pros and cons of CytoDyn Inc_INT for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Standard Investments for future growth
Valuable balance sheet
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Very Future proof/growth oriented business model
Cons
Significant cyclical dependencies
High valuation
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Little known brand

Comments by geldnutzer for this prediction

In the thread CytoDyn Inc diskutieren
Prediction Sell
Perf. (%) -30.80%
Target price 1.200
Change
Ends at 10.07.22

Sell mit Kursziel 1,2

Prediction Sell
Perf. (%) -30.80%
Target price 1.000
Change
Ends at 10.07.22

Kursziel geändert auf 1,0

Prediction Sell
Perf. (%) -30.80%
Target price 0.800
Change
Ends at 10.07.22

Kursziel geändert auf 0,8

In the thread Trading CytoDyn Inc
Prediction Buy
Perf. (%) -30.80%
Target price 0.800
Change
Ends at 10.07.22

Sell beendet

Stopped prediction by geldnutzer for CytoDyn Inc_INT

CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.29
02.03.23
€0.10
02.03.24
-25.70%
03.03.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
buy
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.33
27.02.23
€0.50
27.02.24
-10.72%
02.03.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.34
19.11.22
€0.10
19.11.23
-5.60%
27.02.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
buy
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.65
21.07.22
€0.60
21.07.23
-46.97%
19.11.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.66
09.01.22
€0.20
09.01.23
-1.09%
21.07.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
buy
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€0.88
20.12.21
€1.20
20.12.22
-25.64%
09.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
buy
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€2.26
04.11.20
€3.20
04.11.21
-43.45%
10.07.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€2.10
23.10.20
€1.00
04.11.21
7.62%
04.11.20

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies